Literature DB >> 7524520

Molecular mechanisms regulating CD19, CD20 and CD22 gene expression.

J H Kehrl1, A Riva, G L Wilson, C Thévenin.   

Abstract

The CD19, CD20 and CD22 genes encode transmembrane proteins that are of vital importance to B-cell function. Similar to the immunoglobulin (Ig) genes, they are expressed in a lineage-specific and developmentally regulated manner. Here, John Kehrl and colleagues describe how an understanding of the transcriptional regulation of the CD19, CD20 and CD22 genes is leading to valuable insights into some of the important molecular events that occur in B-cell development and differentiation.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7524520     DOI： 10.1016/0167-5699(94)90273-9

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  10 in total

1.  A multi-gene transcriptional profiling approach to the discovery of cell signature markers.

Authors:  Youichiro Wada; Dan Li; Anne Merley; Andrew Zukauskas; William C Aird; Harold F Dvorak; Shou-Ching Shih
Journal:  Cytotechnology       Date:  2010-10-23       Impact factor: 2.058

2.  Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38.

Authors:  T Bourne; M Zukowska-Cooper; M R Salaman; M H Seifert; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

3.  An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells.

Authors:  G Eberl; S Jiang; Z Yu; P Schneider; G Corradin; J P Mach
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

4.  Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Authors:  Gheath Alatrash; Maher Albitar; Susan O'Brien; Xuemei Wang; Taghi Manshouri; Stefan Faderl; Alessandra Ferrajoli; Jan Burger; Guillermo Garcia-Manero; Hagop M Kantarjian; Susan Lerner; Michael J Keating; William G Wierda
Journal:  Br J Haematol       Date:  2009-11-06       Impact factor: 6.998

Review 5.  Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.

Authors:  Josée Golay; Gianpietro Semenzato; Alessandro Rambaldi; Robin Foà; Gianluca Gaidano; Enrica Gamba; Fabrizio Pane; Antonello Pinto; Giorgina Specchia; Francesco Zaja; Mario Regazzi
Journal:  MAbs       Date:  2013-08-08       Impact factor: 5.857

Review 6.  Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Authors:  Michael J E Marshall; Richard J Stopforth; Mark S Cragg
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

Review 7.  A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Muhammad Harun Achmad; Klunko Nataliya Sergeevna; Wanich Suksatan; Walid Kamal Abdelbasset; Maria Vladimirovna Mikhailova; Navid Shomali; Mahboubeh Yazdanifar; Ali Hassanzadeh; Majid Ahmadi; Roza Motavalli; Yashwant Pathak; Sepideh Izadi; Mostafa Jarahian
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

8.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29

9.  Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.

Authors:  Dvir Netanely; Ayelet Avraham; Adit Ben-Baruch; Ella Evron; Ron Shamir
Journal:  Breast Cancer Res       Date:  2016-07-07       Impact factor: 6.466

Review 10.  Targeting B Cells and Plasma Cells in Autoimmune Diseases.

Authors:  Katharina Hofmann; Ann-Katrin Clauder; Rudolf Armin Manz
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.